N-(3-{2-[(2R)-2-(Hydroxymethyl)pyrrolidin-1-yl]pyrimidin-5-yl}benzyl)-N-methylglycinamide dihydrochloride

ID: ALA4059576

PubChem CID: 137634929

Max Phase: Preclinical

Molecular Formula: C19H27Cl2N5O2

Molecular Weight: 355.44

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  CN(CC(N)=O)Cc1cccc(-c2cnc(N3CCC[C@@H]3CO)nc2)c1.Cl.Cl

Standard InChI:  InChI=1S/C19H25N5O2.2ClH/c1-23(12-18(20)26)11-14-4-2-5-15(8-14)16-9-21-19(22-10-16)24-7-3-6-17(24)13-25;;/h2,4-5,8-10,17,25H,3,6-7,11-13H2,1H3,(H2,20,26);2*1H/t17-;;/m1../s1

Standard InChI Key:  BFILLIIJBSZIRD-ZEECNFPPSA-N

Molfile:  

     RDKit          2D

 28 28  0  0  0  0  0  0  0  0999 V2000
   10.9899  -11.8800    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   12.2138   -8.4456    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5160   -9.6738    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.5085   -8.8566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2104   -7.6285    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.9266   -8.8477    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.8107  -10.0889    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1020   -9.6827    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3967  -10.0978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6839   -9.6916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6805   -8.8744    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3858   -8.4635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0945   -8.8655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5680  -10.9328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5646  -10.1156    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.2699   -9.7005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9786  -10.1067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.9861  -10.9239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2767  -11.3349    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.8627  -11.3438    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.2247  -10.0800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.1125  -11.0160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5688  -11.6248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9798  -12.3301    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7775  -12.1571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3860  -12.7025    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2179  -13.5022    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.9628  -11.9143    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  3  4  1  0
  2  4  1  0
  2  5  2  0
  2  6  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
  8 13  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 14 19  2  0
 14 20  1  0
 10 17  1  0
  3  7  1  0
  3 21  1  0
 20 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 20  1  0
 25 26  1  1
 26 27  1  0
M  END

Associated Targets(Human)

CYP2C19 Tchem Cytochrome P450 2C19 (29246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AOC3 Tchem Amine oxidase, copper containing (450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 355.44Molecular Weight (Monoisotopic): 355.2008AlogP: 1.02#Rotatable Bonds: 7
Polar Surface Area: 95.58Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.29CX LogP: 0.87CX LogD: 0.62
Aromatic Rings: 2Heavy Atoms: 26QED Weighted: 0.77Np Likeness Score: -1.15

References

1. Yamaki S, Koga Y, Nagashima A, Kondo M, Shimada Y, Kadono K, Moritomo A, Yoshihara K..  (2017)  Synthesis and pharmacological evaluation of glycine amide derivatives as novel vascular adhesion protein-1 inhibitors without CYP3A4 and CYP2C19 inhibition.,  25  (15): [PMID:28601507] [10.1016/j.bmc.2017.05.059]

Source